GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress
14.9.2022 18:09:00 EEST | Business Wire | Press release
Galderma has announced it will be showcasing its latest scientific updates at the 31st European Academy of Dermatology and Venereology (EADV) congress in Milan, September 7-10, 2022. These include on-site clinical data presentations, a symposia series and booth activities, all focusing on serving patients by providing options across the Therapeutic Dermatology, Dermo-cosmetics and Injectable Aesthetics categories. As the pure-play dermatology leader, Galderma’s significant presence at EADV reaffirms its commitment to delivering a truly innovative, science-based portfolio of premium cutting-edge brands and services.
The latest science presented by Galderma at EADV reflects the company’s significant investments in research and development with large trials across multiple indications for severe conditions such as prurigo nodularis, atopic dermatitis, acne, rosacea, non-melanoma skin cancer and onychomycosis. For over 40 years, Galderma has solely focused on dermatology and has proven to be one of the few players capable of providing not only best-in-class product solutions but also first-in-class solutions with new innovative modes of action. Today, Galderma is a leading scientific voice in these disease areas and remains committed to delivering further advances for patients with these and other severe skin concerns.
One of the most awaited updates from the company this year will be a focus on IL-31, a neuroimmune cytokine that has been demonstrated to be a central mediator in prurigo nodularis and atopic dermatitis. The cytokine acts as a bridge between the immune and nervous systems and plays a crucial role in igniting and fueling the pathophysiological aspects, including itch and inflammation1,2. Two symposia and eight scientific posters will examine the disease burden, the role of IL-31 in these inflammatory skin conditions and treatments under development.
Another area of focus for Galderma will be on sensitive skin, which affects a major portion of the population with over 70% of women reporting suffering from its effects3. With its strong consumer skin range dedicated to sensitive skin including Cetaphil and the recent acquisition of Alastin Skincare, Galderma understands the need for specifically designed treatments and personalized skincare regimes. At the EADV this year, Galderma, along with key opinion leaders, will be challenging the existing paradigms on sensitive skin and challenging the community on whether it should be considered as a standalone skin condition.
Other skin conditions that drive patients to their dermatologist are acne, rosacea, actinic keratosis and non-melanoma skin cancer, conditions that affect a significant cross-section of society. Galderma has been researching these conditions and bringing innovative products to patients and consumers for decades. At EADV, the company will present new data and host scientific meetings and discussions to look at novel patient-centered, holistic approaches in each of these areas to support the identification of the best personalized treatment regimens for each patient.
Galderma’s significant presence at EADV this year reflects its expertise across these common and often severe skin conditions and is testament to its commitment to advancing dermatology for every skin story.
|
“We look forward to engaging with the dermatology community at the
BALDO SCASSELLATI SFORZOLINI, M.D.
|
Below is a full list of activities taking place.
Prurigo nodularis and atopic dermatitis
- Thinking differently about atopic dermatitis: It’s time for a new perspective – September 9, 1:00 PM - 2:00 PM CEST (Room: AMBER 3 and 4). Chaired by Professor Diamant Thaçi (Germany) and featuring Professor Marjolein de Bruin-Weller (Netherlands) and Professor Andreas Wollenberg (Germany)
- Navigating new data in prurigo nodularis: restoring hope for patients – September 10, 1:00 PM - 2:00 PM CEST (Room: CORAL 6). Chaired by Professor Sonja Ständer (Germany) and Professor Giampiero Girolomoni (Italy), and featuring Professor Doctor Shawn Kwatra (U.S.) and Professor Doctor Bernhard Homey (Germany)
Sensitive skin
- Simplifying sensitive skin: can we define it as a standalone skin condition? – September 7, 1:00 PM - 2:00 PM CEST (Room: CORAL 6). Chaired by Professor Giovanni Pellacani (Italy) and featuring Professor Adam Friedman (U.S.) and Doctor Krzysztof Piotrowski (Switzerland)
Acne
- A novel patient-centered approach for acne management – September 8, 1:00 PM - 2:00 PM CEST (Room: CORAL 6). Co-chaired by Professor Alison Layton (UK) and Professor Doctor Jerry Tan (Canada), and featuring Doctor Vincenzo Bettoli (Italy)
- Opportunities for a holistic approach to acne vulgaris management – September 9, 9:15 AM -10:00 AM CEST (Room: HUB 2.05). Featuring Professor Brigitte Dreno (France), Professor Gabriella Fabbrocini and Doctor Magda Belmontesi (Italy)
- Acne update: Recent advances on skin microbiome, strain co-residence of C. acnes and treatment best practices – September 9, 4:00 PM - 4:45 PM CEST (Room: HUB 2.08). Featuring Professor Brigitte Dreno (France) and Professor Tami Lieberman (U.S.)
Rosacea
- Clinical challenges in rosacea: overcoming obstacles on the road to treatment optimization – September 8, 6:00 PM - 7:30 PM CEST (Room: CORAL 6). Featuring Professor Doctor Giuseppe Micali (Italy), Professor Doctor Martin Schaller (Germany) and Professor Doctor Jerry Tan (Canada)
Actinic keratosis / non-melanoma skin cancer
- An integrated approach for actinic keratosis and non-melanoma skin cancer management – September 8, 2:30 PM - 3:15 PM CEST (Room: HUB 2.03). Chaired by Professor Merete Haedersdal (Denmark) and featuring Professor Claas Ulrich (Germany) and Doctor Magda Belmontesi (Italy)
- Beyond the lesion: Expert recommendations for longitudinal, patient-centered actinic keratosis management – September 9, 6:00 PM - 7:30 PM CEST (Room: AMBER 3 and 4). Co-chaired by Professor Rolf-Markus Szeimies (Germany) and Professor Colin Morton (UK) and featuring Professor Piergiacomo Calzavara-Pinton (Italy)
- Personalizing Actinic Keratosis Treatment (PAKT): Expert recommendations to support patient-centered management of actinic keratosis (oral presentation) – September 10, 10:15 AM CEST (Room: BROWN 2, FC05: Free comms in cutaneous oncology and genetics). Featuring Professor Rolf-Markus Szeimies (Germany)
Onychomycosis
- Onychomycosis update: Quantified penetration profile of topical amorolfine in infected human nails – September 8, 9:15 AM - 10:00 AM CEST (Room: HUB 2.01). Featuring Professor Martin Schaller (Germany)
A broad range of new scientific data posters has been accepted for EADV this year and can be provided upon request.
About Galderma
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermo-Cosmetics and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. Galderma’s portfolio of flagship brands includes Restylane, Dysport, Azzalure, Alluzience and Sculptra in Injectable Aesthetics; Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac and Loceryl in Therapeutic Dermatology; and Cetaphil and Alastin in Dermo-cosmetics. For more information: www.galderma.com.
References
1.Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmakoi.2021;14(1):67-77. doi:10.1080/17512433.2021.1852080
2. Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med (Lausanne). 2021;8: 639097. doi:10.3389/fmed.2021.639097
3. Farage, Miranda A. “The Prevalence of Sensitive Skin.” US National Library of Medicine National Institutes of Health, www.ncbi.nlm.nih.gov/pmc/articles/PMC6533878.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005330/en/
Contact information
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Rachel Mooney
Global Franchise Communications
rachel.mooney@galderma.com
+41 76 261 64 41
Tracy Krumme
Global Head of Investor Relations
investors@galderma.com
+1-817-961-5530
Sébastien Cros
Corporate Communications Director
Sebastian.cros@galderma.com
+41 79 529 59 85
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logistics Reply Expands Robot-Assisted Fulfilment at The Quality Group19.11.2026 11:00:00 EET | Press release
Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the site manage highly dynamic order volumes and process up to 100,000 orders per day across its 50,000-square-metre facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119787784/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the sit
Twilio Powers Chelsea FC to Cut Campaign Launch Times from 48 Hours to Under 15 Minutes19.11.2026 11:00:00 EET | Press release
Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its SIGNAL World Tour London, by unveiling that Chelsea Football Club has slashed campaign launch times from 48 hours to under 15 minutes with Twilio Segment. Building a Single View of the Global Fan Chelsea’s global fans interact with the Club across matchdays, ticketing, its mobile app, ecommerce and other digital experiences. Historically, these interactions sat across siloed systems, creating duplicate customer records for a single fan. By consolidating its data, Chelsea removed over 460,000 duplicate records. With this cleaner and unified fan database, campaign launch time has been reduced from 48+ hours to under 15 minutes. Beyond the Pitch: Elevating the Fan Experience Chelsea is now able to send its fans highly relevant messages tailored to them right as the action happens on the pitch. With Twilio Segment, Chelsea is able to: Create Real-Time Offers: After Estêvão Willian’s extraordinary
EDAN Presents Integrated Medical Innovations at MEDICA 2026, Strengthening Global Healthcare Connections19.11.2026 10:49:00 EET | Press release
Edan Instruments, Inc. (300206. SZ), a global provider of medical devices and healthcare solutions, is presenting its latest innovations at MEDICA 2026, taking place November 16–19 in Düsseldorf. The event provides an important platform for industry exchange and an opportunity for EDAN to engage with European partners on evolving healthcare needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118813326/en/ “Germany and Europe are important partners in the global healthcare industry. As China’s medical technology sector expands internationally, closer collaboration with European healthcare professionals and industry partners can create opportunities for shared progress,” said Alex You, Senior Director of Marketing, Customer Service, Global Connectivity & Integration at EDAN. “By understanding local clinical needs and translating them into accessible, reliable solutions, we can contribute to more effective healthcare. MEDI
Ant International's Alipay+ to Connect over 50 Global E-Wallets with Pix of Brazil19.11.2026 10:43:00 EET | Press release
Ant International today announced that Alipay+, its global wallet gateway that links over 50 global digital wallets and banking apps, is connected to Pix, Brazil's national instant payment system, expanding cross-border digital payment access for international travellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119229229/en/ Ant International's global wallet gateway Alipay+ is connecting over 50 e-wallets and banking apps to Pix Powered by Ant International’s AI-native payment and risk management capabilities, the service allows international travellers using their familiar payment apps to scan Pix QR codes at shops, restaurants, and attractions nationwide, without downloading a new app. The launch is part of Alipay+'s broader efforts to advance cross-border digital payment connectivity. Through its payment partners, Alipay+ links 150 million merchants with 2.1 billion user accounts globally. It also partners with
Summit Risk Partners Limited Opens for Business as a Registered Lloyd’s Broker Through its Regulated Subsidiaries19.11.2026 10:00:00 EET | Press release
Summit Risk Partners Limited (SRP), a newly launched division of K2 Insurance Services, announced today it is officially open for business as a registered Lloyd’s broker. Built specifically for the future of delegated authority, SRP aims to elevate service provision and set a new standard for outcomes across delegated and programme business in the Lloyd’s and London markets. Co-founded by James Baird, CEO, and Jamie Beckett, Managing Director, the specialist broking house operates free from legacy systems and mindsets. SRP combines deep industry expertise with modern technology, actionable insight, and a relentless focus on client success for coverholders, MGAs, underwriting businesses and capacity providers. Key Operational Highlights: Market Status: Registered Lloyd’s broker trading under the pseudonym SUM (Broker Number 2336), sponsored by three leading Lloyd’s Managing Agents. Footprint: Operates in the UK through Summit RP GmbH (UK Branch), an appointed representative of K2 Group
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
